Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment

Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment

US Patent 9763980 · Granted Sep 19, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

RGMC-selective inhibitors and use thereof2025
Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathi2025
Methods for inducing hematopoietic stem cell specificity2025
Endothelial cell factors and methods thereof2024
Methods and agents that enhance myogenic progenitor cell engraftment2024
Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of r2024
Method of preparing hematopoietic stem and progenitor cells for transplantation2024
Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathi2023
Methods and agents that enhance myogenic progenitor cell engraftment2022
Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathi2021
Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of r2021
Method to enhance tissue regeneration2020